Keyphrases
Doxorubicin
100%
PXD101
50%
Associated Risk Factors
50%
Sarcoma
50%
Cardiotoxicity
50%
Soft Tissue Sarcoma
50%
Belinostat
50%
Phase III Clinical Trial
50%
Left Ventricular Ejection Fraction
22%
Response Rate
22%
Maximum Tolerated Dose
11%
Dose-limiting Toxicity
11%
Diastolic Blood Pressure
9%
Equilibrium Radionuclide Angiography
9%
Cadmium Zinc Telluride
9%
Chemotherapy
9%
High Risk
9%
PR-1
5%
Rash
5%
Solid Tumors
5%
Dose Escalation
5%
One Dose
5%
Adverse Events
5%
Toxicity Grades
5%
Time to Progression
5%
Median Time
5%
IV Infusion
5%
Alopecia
5%
Nausea
5%
Histone Deacetylase Inhibitor (HDACi)
5%
Medicine and Dentistry
Doxorubicin
100%
Cardiotoxicity
50%
Sarcoma
50%
Belinostat
50%
Soft Tissue Sarcoma
50%
Clinical Trial
50%
Heart Left Ventricle Ejection Fraction
19%
Diastolic Blood Pressure
7%
Radionuclide Ventriculography
7%
Hand Rash
5%
Solid Malignant Neoplasm
5%
Adverse Event
5%
Histone Deacetylase Inhibitor
5%
Infusion
5%
Alopecia Mucinosa
5%
Nausea
5%
Pharmacology, Toxicology and Pharmaceutical Science
Doxorubicin
100%
Sarcoma
50%
Cardiotoxicity
50%
Soft Tissue Sarcoma
50%
Clinical Trial
50%
Belinostat
50%
Maximum Tolerated Dose
10%
Chemotherapy
7%
Radioisotope
7%
Cadmium Zinc Telluride
7%
Hand Rash
5%
Syndrome
5%
Histone Deacetylase Inhibitor
5%
Solid Malignant Neoplasm
5%
Adverse Event
5%
Nausea
5%
Alopecia
5%
